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Purpose: The aim of this study was to determine the level of consensus among Italian health 
care professionals (HCPs) regarding factors that influence adherence to cystic fibrosis (CF) 
treatments.
Methods: A Delphi questionnaire with 94 statements of potential factors influencing adherence 
was developed based on a literature review and in consultation with a board of experts (n=4). 
This was distributed to a multidisciplinary expert panel of HCPs (n=110) from Italian CF centers. 
A Likert scale was used to indicate the level of agreement (1= no agreement to 9= maximum 
agreement) with each statement. Three rounds were distributed to establish a consensus ($80% 
of participant ratings within one 3-point region) and, at the third round, assign a ranking to each 
statement with a high level of agreement (consensus in the 7–9 range) only.
Results: Of 110 HCPs (from 31 Italian CF centers who were surveyed), responses were 
obtained from 85 (77%) in the first, 78 (71%) in the second, and 72 (65%) in the third round. 
The highest degree of agreement (95.8%) was reached with the statement that the HCP needs 
to build a relationship with the patient to influence adherence. A high level of agreement was 
not reached for statements that morbidity and mortality are influenced by the level of adherence 
to therapy, and no consensus was reached on the statement that age of the patient influences 
adherence to treatment.
Conclusion: We found that Italian HCPs endorsed a strong relationship with the patient as being 
a key driver in improving adherence. There were several areas, such as the influence of adherence 
on morbidity and mortality, where the consensus of Italian HCPs differed from the published 
literature. These areas require investigation to determine why these discrepancies exist.
Keywords: cystic fibrosis, long-term adherence, Delphi technique
Introduction
Cystic fibrosis (CF) is a lifelong, complex multisystem disease with significant 
challenges in treatment management. Treatments can be burdensome, time-consuming, 
and costly;1,2 the daily regimen can require ingestion of as many as 40–50 pills, 
inhalation treatments lasting up to 2 hours, and 2–3 airway clearance sessions of 
30 minutes each.3 Equipment maintenance and preparation of medications, in addition 
to administrative barriers to maintaining access to medications, add to the time burden.4 
As reported in the World Health Organization (WHO) document,5 poor adherence 
to long-term therapies severely compromises the effectiveness of treatment, making 
adherence a critical issue in the management of patients with chronic diseases.
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Poor adherence is considered the single greatest cause 
of treatment failure,6 and results in increased morbidity and 
mortality, a reduction in quality of life, and increased health 
care use and costs.7,8 Adherence rates for CF treatments are 
generally below 50%;9,10 however, objective assessment 
tools are rarely used, with the vast majority of CF centers 
relying on clinical impression.11 In both children and adults 
with CF, adherence decreases when the complexity of the 
regimen increases.12 Rates of adherence are higher with oral 
medications, lower with nebulized treatment and pancreatic 
enzymes, and lowest with vitamin treatment, dietary changes, 
exercise, and physiotherapy.13–18 In children whose parents 
strongly believe the treatment is necessary, better adherence 
is more likely.19
With improved patient survival, long-term management 
of CF has become an important focus, but treatment demands 
become repetitive and burdensome over the course of the 
disease, making long-term adherence challenging.13 Patients 
often carry out a personal cost–benefit analysis, assessing 
costs against the perceived necessity for, and their concerns 
about, their treatment regimen.19 In addition, patients with 
CF are faced with new challenges as they age, such as the 
transfer of responsibility for their medical treatment (from 
parents/caregivers to themselves) during the transition from 
adolescence to adulthood.20,21
In the recent update to the European Cystic Fibrosis Stan-
dards of Care: Best Practice Guidelines in the treatment of 
CF, the core components to addressing adherence were deter-
mined to be: team ethos with respect to patient care, collabo-
ration with patients, identification of the barriers to adherence, 
and active support of patients’ efforts.22 Adherence to treat-
ment regimens can be influenced by many emotional factors, 
including dependency, feeling different, embarrassment at 
taking drugs in public places, effect on personal freedom, 
and significant influence on lifestyle. Usually, the focus is 
on patient-related factors, while the provider- and health 
system-related determinants of nonadherence, which can 
have a major effect, are neglected.23
The aim of this multicenter study was to investigate the 
level of consensus among Italian health care professionals 
(HCPs) on issues identified in the literature as influencing 
adherence to treatments in patients with CF. The study sought 
to identify areas of consensus and disagreement with the 
literature. The goal was to identify educational needs among 
Italian HCPs in order to develop a program of instruments, 
actions, and operational modalities (applicable in clinical 
practice) to support and enhance patients’ long-term adher-
ence to treatment.
Methods
The Delphi process, developed in the 1950s,24 is a commu-
nication process widely used to establish consensus among 
experts when there is insufficient evidence to determine an 
objective answer. The process has been widely applied to 
health-related research,25,26 and involves a panel of experts 
anonymously completing a series of structured question-
naires, with the responses provided to the participants between 
rounds and amended in subsequent rounds, until a consensus 
is reached. The structure of the process is designed to allow 
group consensus without direct confrontation and to allow 
participants to gather opinions and react in subsequent rounds. 
Review and approval of this study by an institutional review 
board or ethics committee were not required as no patient data 
were obtained. By completing and returning the questionnaire, 
each participant consented to being involved in the study.
We first established a multidisciplinary expert board 
(two physicians, one psychologist, and one physiotherapist) 
and then implemented a bibliographic search of articles 
in PubMed, published in English language journals after 
January 1, 1995, using the keywords “compliance” OR/AND 
“adherence” AND “cystic fibrosis” OR/AND “cystic fibro-
sis therapy” AND “motivational interviewing” OR/AND 
“physician–patient relations”. Thirty-one papers were iden-
tified (one randomized controlled trial, 17 observational 
studies, six reviews, five systematic reviews, one opinion, 
and one state-of-the-art review) and sent to the members of 
the expert board.
Our review of this collection of manuscripts identi-
fied 165 statements related to treatment adherence among 
patients with CF, which were used to create a questionnaire 
(in Italian). No pilot testing was conducted; however, each 
assumption was evaluated three times, first independently 
by each member of the expert board via e-mail, followed by 
two collective teleconferences, with a final meeting to refine 
and validate each assumption. At the end of the selection 
process, duplications and redundancies were eliminated, and 
94 statements were considered for the Delphi questionnaire 
and divided into three areas: “General Aspects” (six cat-
egories), “Roles and Relational Aspects” (three categories), 
and “Management Aspects” (four categories). A Likert scale 
was used by the respondents to evaluate the level of agree-
ment with each of the statements in the questionnaire (1= no 
agreement to 9= maximum agreement). All activities were 
coordinated by a facilitator.
All Italian specialized centers dedicated to care and 
management of patients with CF were contacted and asked 
for volunteer participation from different HCPs who met 
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the following criteria, as identified by the multidisciplinary 
expert board:
•	 At least 2-years’ experience in the field (for physicians)
•	 In the last 2 years, at least 50% of their weekly work time 
dedicated to patients with CF (for non-physicians)
The questionnaire was sent by e-mail with a maximum 
of three reminders; the answers arrived via e-mail, fax, or 
postal mail.
Definitions for consensus and no consensus were decided 
a priori based on prior literature.27,28 Consensus was defined 
as $80% of participant ratings within one 3-point region 
(1–3= low level of agreement; 4–6= borderline; 7–9= high 
level of agreement). Disagreement was defined as $90% of 
participant ratings within one of two wide ranges (1–6 or 4–9). 
Results outside the ranges for consensus and disagreement 
were defined as no consensus. The collected assessments 
were evaluated for internal consistency and aggregated to 
obtain a composite judgment.
The HCP panel was consulted three times in total. In the 
first round, the questionnaire was distributed and the level 
of agreement among HCPs in relation to each statement was 
determined. In the second round, statements for which there 
was disagreement during the first round were shared with the 
HCP panel, who were allowed to alter their responses from 
the first round. A third round of consultation was conducted 
to apply rankings to each of the statements that had a high 
level of agreement following rounds one and two. Rankings 
were assigned within each of the three areas with one state-
ment defined as the highest rank.
The flow chart of the analysis is presented in Figure 1. 
Calculations for the analysis were performed using Micro-
soft Excel 2007 software package (Microsoft Corporation, 
Redmond, WA, USA).
Results
The analysis was conducted in Italy from January 2015 to 
June 2015. All 32 CF centers in Italy were contacted and a 
total of 110 HCPs from 31 centers participated in the study. 
The distribution of HCP categories responding in the first 
round (n=85) is presented in Figure 2; the inclusion criteria 
for volunteers resulted in the participation of a multidisci-
plinary expert panel of HCPs. Although participation in the 
study was purely voluntary, the response rate remained high 
throughout. Responses were obtained from 85 HCPs (77%) 
in the first round and 78 (71%) and 72 (65%) HCPs in the 
second and third rounds, respectively.
Participation was lower among physicians (64%) and 
higher among nurses (93%), physiotherapists (95%), and 
psychologists (100%). The distribution of respondents in the 
second and third round did not vary greatly when compared 
with the first round, with physicians’ participation at 59% in 
the second round and 55% in the third round, nurses’ partici-
pation at 86% in both rounds, physiotherapists’ participation 
Figure 1 Process flow chart.
Note: Calculations for the analysis were performed using Microsoft Office 2007 
software package (Microsoft Corporation, Redmond, WA, USA).
????????????????????
?????????????????
?????????????????????
?????????????????????????
????????????????????????
????????????????????????????
???????????????????????????
???????????????
Figure 2 Distribution of HCP categories among responders to the first round of 
the Delphi analysis (total number of responders =85).
Abbreviation: hcP, health care provider.
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at 80% and 75%, and psychologists’ participation at 100% 
and 71%, respectively.
Tables S1–S3 show results for all 94 statements evaluated 
in the first and second round, and the rankings assigned (for 
statements with high-level agreement).
A high level of agreement was obtained from the first 
round on 37 statements ($80% of responses in regions 7–9) 
and a low level of agreement ($80% of responses in regions 
1–3) only on one statement. After the second round, level 
of agreement was similar to the first round; therefore, a 
third round was conducted only to assign a rank to the 
40 statements with a high level of agreement (seven in 
“General Aspects”, 12 in “Roles and Relational Aspects”, 
and 21 in “Management Aspects”), representing 45% of all 
statements.
Figure 3 presents the ranked scores for statements in 
the “General Aspects” area. The highest level of agreement 
(first-level ranking) was the statement “Adherence means 
agreeing to one’s own treatment plan and committing to 
follow it” (83.1%). Of interest, the treating team’s com-
munication skills were deemed more important (in terms of 
influencing adherence to treatment in patients with CF) than 
a physician’s ability to communicate.
Statements assigned a rank in the “Roles and Relational 
Aspects” area are presented in Figure 4. A very high level of 
agreement (95.8%) was reached on the statement affirming 
that building a relationship with the patient is necessary to 
influence treatment adherence, which was assigned a first-
level ranking. All the statements in the “Roles and Relational 
Aspects” area confirmed the following: the perception of the 
important role of individual HCPs as well as treating the HCP 
team as a whole; the accuracy of information conveyed to the 
patient; the patient’s comprehension of that information and 
the patient guiding change; the ability to listen and to discuss; 
the need to share the interventions dedicated to supporting 
adherence and for interventions to be consistent; and the need 
to define treatment objectives step by step.
Statements assigned a rank in the “Management Aspects” 
area are presented in Figure 5. Of note is the high level of 
agreement among all HCPs on almost all statements in the 
“Management Aspects” area (21 out of 29 statements). The 
quality of communication and the need to have a structured 
Figure 3 Ranking of statements with a high level of agreement in the “General Aspects” area.
Note: results from all 38 statements are provided in Table S1.
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and consistent approach through a personalized, collab-
orative, open dialogue with the patient were unanimously 
evaluated as important.
All statements, including those that did not reach a 
consensus, are presented in Tables S1–S3. In addition, 
differences in opinion between HCPs (as identified in the 
first round) are presented in Tables S4–S6. The level of 
agreement for statements regarding morbidity and mortality 
being influenced by adherence to therapy was lower than 
for other items (such as those describing both internal and 
external factors influencing adherence); different levels of 
agreement were found between the different professionals 
in the treating team. Physicians tended to agree more than 
other HCPs that morbidity is influenced by adherence. Con-
sensus was not reached for the statements that the age of the 
patient influences adherence to treatment, or that adherence 
is a problem for the adolescent patient.
Among the “Management Aspects”, 14% of the HCPs 
surveyed reached a low agreement (responses in regions 
1–3) on the issue of “understanding without judging the 
patient”.
Discussion
Various barriers to adherence to CF treatments have been 
described, including lack of time, forgetfulness, unwilling-
ness to take medication in public, high level of polypharmacy, 
poor patient–HCP communication, lack of disease- and 
treatment-related knowledge, and the patient’s or caregiver’s 
beliefs.29 The Italian HCPs surveyed in our study reached 
a high level of agreement with almost half of the factors 
that influence adherence identified in the literature. These 
findings are important in order to provide suggestions about 
new interventional studies, educational materials needed 
for HCPs, and operational modalities applicable in clinical 
Figure 4 Ranking of statements with a high level of agreement in the “Roles and Relational Aspects” area.
Note: Results from all 27 statements are provided in Table S2. 
Abbreviation: hcP, health care provider.
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practice to support and enhance patient’s long-term adher-
ence to treatment.
A strong relationship between the patient and the CF-
treating team was endorsed as a key driver of improved 
adherence in previous studies30,31 and by the Italian HCPs 
surveyed. Establishing effective communication and interac-
tion between patients, their families, and caregivers is one 
of the most important, and potentially one of the simplest, 
approaches to increase adherence in CF. Even considering 
the distinct functions of the different HCPs in treating CF, 
focusing on the patient rather than the disease can reduce 
differences in the perceptions of what each HCP can do to 
encourage and support the patient’s adherence to treatments 
in the long term. In a large meta-analysis of studies conducted 
between 1949 and 2008, the probability of adherence was 
2.1 times greater for patients treated by a physician who 
was classified as a good communicator.32 A collaborative 
approach centered on patient care was also found to be 
Figure 5 Ranking of statements with a high level of agreement in the “Management Aspects” area.
Note: results from all 29 statements are provided in Table S3. 
Abbreviation: hcP, health care provider.
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important in motivating patients.31,33 New approaches to 
training and training activities to increase competencies in the 
use of novel patient-centered tools, such as the motivational 
interview,34 are important, and needed, but should be inves-
tigated through interventional studies incorporating them 
into daily standard clinical activities. Although a high level 
of agreement was reached between HCPs after the second 
round, representing 45% of all statements, agreement was not 
obtained for the remaining statements (eg, “The mortality/
morbidity of patients with cystic fibrosis is influenced by the 
level of adherence to the therapeutic prescriptions received” 
and “Adherence is influenced by the age of the patient”). 
It is useful to determine on which statements HCPs did 
not reach an agreement, as this can stimulate interest and 
inform future discussions and the development of focused 
training plans. However, in some instances, the low level 
of agreement among HCPs could be a result of differences 
in the interpretation of questions or slight semantic differ-
ences. There were also some notable discrepancies between 
the level of agreement among the Italian HCPs surveyed 
and the published literature. The influence of adherence on 
morbidity and mortality has been well described,8 as has the 
fact that younger patients tend to have higher rates of treat-
ment adherence than adolescents and adults.35 However, in 
our study of Italian HCPs, a high level of agreement was not 
reached on these statements. These discrepancies could be 
explained by the differences in roles within the treating team; 
physicians oversee the management of patients with CF and 
seem more conscious of morbidity outcomes and the overall 
consequences of low adherence, while other HCPs, such as 
physiotherapists and psychologists, are focused on specific 
aspects of the management of CF patients. Furthermore, the 
views of Italian HCPs could be influenced by local factors, 
such as the Italian education system and cultural beliefs 
and/or values, which could account for the discrepancies 
observed. Additional research will be necessary to determine 
why these discrepancies exist between the opinions of HCPs 
and the published literature and to develop educational pro-
grams and training materials to ensure that HCPs are aware 
of the influence of these factors on adherence to treatment.
Limitations
Our descriptive, non-interventional study has several limita-
tions. First, the multidisciplinary expert board consisted of 
only four HCPs; however, one of these HCPs is head of the 
Società Italiana Di Fibrosi Cistica (SIFC, a national scientific 
society) working group on adherence, of which the remaining 
three HCPs are all members. This was agreed to be sufficient 
for the purposes of this study. Second, the HCPs surveyed 
represent a self-selected population that is engaged enough 
to commit to three rounds of surveys and may not be rep-
resentative of other HCPs. Although HCPs were engaged, 
participation rates decreased slightly between rounds, which 
may be due to reasons such as attrition, reduced personal 
motivation, or the amount of time required to complete the 
requested rounds of consultation. While the participation 
rate was lower among physicians than with psychologists, 
the physician participation rate was still relatively high, 
with the difference observed between professions possibly 
due to greater motivation among psychologists to complete 
questionnaires on this topic. We also only included HCPs 
from Italian CF centers; therefore, the results cannot neces-
sarily be applied to other European or North American CF 
centers. Adherence was not explicitly defined, although 
several statements addressed how the HCPs defined adher-
ence (eg, “agreeing to one’s own treatment plan and com-
mitting to follow it”; “an individual behavior comprising the 
degree of concordance with the medical advice received”). 
Furthermore, the Delphi poll measured HCPs’ beliefs about 
what affected long-term medication adherence. However, 
medication adherence is a patient behavior, and not a HCP-
related behavior. Therefore, the actual driving force behind 
medication adherence may be different to that considered 
by HCPs in determining why patients continue to take their 
medications, or not. An additional limitation is that there is 
no universally agreed definition of consensus, with several 
factors, such as the number of respondents, aim of the 
research, and resources, influencing the cutoff.26 Even with 
these limitations, the Delphi technique has been established 
as a valuable means for structuring group discussion among 
experts and raising issues for debate.
Conclusion
We have identified important areas of consensus and dis-
agreement regarding factors that influence adherence to 
CF treatments among Italian HCPs. To Italian physicians, 
adherence generally means the patient agrees to and commits 
to following a specific treatment plan; a strong physician–
patient relationship is a key factor in influencing adherence. 
More standard measures of adherence (medication possession 
ratio or proportion of days covered) rely solely on a patient’s 
medication refill history and do not account for additional 
factors that might influence adherence (eg, the patient taking 
the medication in the correct way). These results are a first 
step in developing training tools and educational materials 
to work with HCPs to improve the overall adherence to 
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treatment, which can ultimately lead to improved long-term 
outcomes.
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